NAVEEN PEMMARAJU to Clinical Trials as Topic
This is a "connection" page, showing publications NAVEEN PEMMARAJU has written about Clinical Trials as Topic.
Connection Strength
0.388
-
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 09 10; 40(26):3032-3036.
Score: 0.102
-
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021 05; 18(5):313-319.
Score: 0.093
-
Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am. 2020 06; 34(3):565-574.
Score: 0.087
-
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Cancer. 2011 Aug 01; 117(15):3293-304.
Score: 0.046
-
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol. 2022 07; 97(7):885-894.
Score: 0.025
-
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 11 15; 132(20):2115-2124.
Score: 0.020
-
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 May; 2(5):e186-93.
Score: 0.015